HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chattem absorbs costs as Sanofi deal nears close

This article was originally published in The Rose Sheet

Executive Summary

The Chattanooga, Tenn., company nudged revenue up 1.9% in fiscal 2009 to $463.3 mil., helped by 4.5% increase in the fourth quarter to $110.2 mil. Full-year net income reached $63.2 mil., a 4.7% dip, the firm said Jan. 28. However, Chattem absorbed a net loss of $4.1 mil. in the three months ended Nov. 30, due to early extinguishment of debt, employee stock option expenses and a non-cash impairment of intangible assets related to the firm's dietary supplement business. Chattem's supplements - including Dexatrim, Garlique and Melatonex - represent about 4% of annual sales. The company did not hold an earnings call to report its financial results, with its acquisition by Sanofi-Aventis near completion (1"The Rose Sheet" Jan. 4, 2010). The French pharma announced Jan. 26 the waiting period under the Hart-Scott Rodino Act passed and the tender offer for all outstanding Chattem shares - at $93.50 each - is set to expire Feb. 8

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts